Milestone Scientific Projects 400% CompuFlo Sales Growth, $9.8M–$10.2M 2026 Revenue
Milestone Scientific’s Q4 revenue rose 2.2% to $2.1 million, while operating loss improved 89% to $1.1 million and revenue grew 4% to $9.0 million with $5.7 million loss. 2026 revenue of $9.8–$10.2 million will be driven by a 400% CompuFlo sales increase to $500K–$600K, targeting cash-flow breakeven by early 2027.
1. 2025 Financial Results
Milestone Scientific reported Q4 2025 revenue of $2.1 million, up 2.2% year-over-year, alongside an operating loss of $1.1 million, an 89% improvement. Full-year revenue rose 4% to $9.0 million with a $5.7 million net loss, ending the year with $1.1 million in cash and $3.3 million in working capital.
2. Operational Restructuring and Growth Programs
Since appointing new leadership in August 2025, the company enforced stricter capital allocation, eliminating non-revenue spending and reallocating resources to revenue-driving initiatives. The dental ambassador pilot launched in December, CompuFlo commercialization was relaunched, digital marketing spend increased, and new distribution and registration efforts advanced in key international markets.
3. 2026 Outlook and Breakeven Goal
For 2026, management forecasts revenue of $9.8–$10.2 million, led by a 400% surge in CompuFlo sales to $500K–$600K. Selective investments in sales programs and continued dental strength aim to improve operating leverage and achieve cash-flow breakeven by early 2027.